ASKP1240 in De Novo Kidney Transplant Recipients

被引：0
|
作者：
Harland, R. [1 ]
Klintmalm, G. [2 ]
Yang, H. [3 ]
Jensik, S. [4 ]
Shah, T. [5 ]
West-Thielke, P. [6 ]
Shihab, F. [7 ]
Zhang, W. [8 ]
Santos, V. [8 ]
Tainaka, R. [8 ]
Wang, X. [8 ]
First, R. [8 ]
Holman, J. [8 ]
机构：
[1] E Carolina Univ, Greenville, NC USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Pinnacle Hlth Syst, Harrisburg, PA USA
[4] Rush Univ, Chicago, IL 60612 USA
[5] Transplant Res Inst, Los Angeles, CA USA
[6] Univ Illinois, Chicago, IL USA
[7] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA
[8] Astellas Pharma Global Dev, Northbrook, IL USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2015年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
3012
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effects of ASKP1240 Combined With Tacrolimus or Mycophenolate Mofetil on Renal Allograft Survival in Cynomolgus Monkeys
    Song, Lijun
    Ma, Anlun
    Dun, Hao
    Hu, Yanxin
    Zeng, Lin
    Bai, Jieying
    Zhang, Guangzhou
    Kinugasa, Fumitaka
    Sudo, Yuji
    Miyao, Yasuhiro
    Okimura, Kazumichi
    Miura, Toru
    Daloze, Pierre
    Chen, Huifang
    TRANSPLANTATION, 2014, 98 (03) : 267 - 276
  • [2] Clinical Outcomes in a Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose Study of ASKP1240 in De Novo Kidney Transplantation.
    Vincenti, F.
    Yang, H.
    Klintmalm, G.
    Steinberg, S.
    Wang, L.
    Zhang, W.
    Conkle, A.
    Blahunka, P.
    First, R.
    Holman, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 86 - 86
  • [3] A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de novo Kidney Transplantation
    Yang, H.
    Vincenti, F.
    Klintmalm, G.
    Steinberg, S.
    Wang, L.
    Zhang, W.
    Conkle, A.
    Shrivastava, A.
    Blahunka, P.
    First, R.
    Holman, J.
    TRANSPLANTATION, 2012, 94 (10) : 80 - 80
  • [4] Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
    Staino, C.
    Pilch, N.
    Moussa, O.
    Boyle, K.
    Casale, J.
    Covert, K.
    Fleming, J.
    Taber, D.
    Meadows, H.
    Mardis, C.
    Chavin, K.
    Nadig, S.
    McGillicuddy, J.
    Bratton, C.
    Srinivas, T.
    Baliga, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [5] A PHASE 1 SINGLE ASCENDING DOSE STUDY OF ASKP1240 (ANTI-CD40 MAB) IN HEALTHY SUBJECTS
    Goldwater, Ronald
    Keirns, James
    Blahunka, Paul
    First, Roy
    Holman, John
    TRANSPLANT INTERNATIONAL, 2011, 24 : 70 - 71
  • [6] De novo cancer in transplant recipients
    Kim, MS
    Kim, SI
    Kim, YS
    Oh, CK
    Park, K
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (03) : 1651 - 1652
  • [7] Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects
    Okimura, K.
    Maeta, K.
    Kobayashi, N.
    Goto, M.
    Kano, N.
    Ishihara, T.
    Ishikawa, T.
    Tsumura, H.
    Ueno, A.
    Miyao, Y.
    Sakuma, S.
    Kinugasa, F.
    Takahashi, N.
    Miura, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (06) : 1290 - 1299
  • [8] Does de novo malignancy increase the risk of rejection in kidney transplant recipients?
    Demir, Erol
    Dincer, Mevlut Tamer
    Karaca, Cebrail
    Erel, Cansu
    Karahan, Latif
    Pekmezci, Aslihan
    Trabulus, Sinan
    Seyahi, Nurhan
    Turkmen, Aydin
    TRANSPLANTATION, 2024, 108 (09) : 363 - 363
  • [9] Effect of denosumab on trabecular bone score in de novo kidney transplant recipients
    Bonani, Marco
    Frey, Diana
    Graf, Nicole
    Wuthrich, Rudolf P.
    SWISS MEDICAL WEEKLY, 2018, 148 : 16S - 16S
  • [10] Infections in De Novo Kidney Transplant Recipients Treated With the RANKL Inhibitor Denosumab
    Bonani, Marco
    Frey, Diana
    de Rougemont, Olivier
    Mueller, Nicolas J.
    Mueller, Thomas F.
    Graf, Nicole
    Wuthrich, Rudolf P.
    TRANSPLANTATION, 2017, 101 (09) : 2139 - 2145
12345